Novel targeted therapy in multiple myeloma

Recently, new agents have explored in the treatment of multiple myeloma (MM), according to the identification of the novel pathogenetic mechanisms. Proteasome inhibitor (bortezomib) and immunomodulatory drugs (thalidomide and lenalidomide) now play important roles in the treatment of MM, and they have resulted in an improvement of the outcome of the patients. However, MM remains incurable and the prognosis is very poor in the patients who become refractory to bortezomib and IMiDs. New agents with novel mechanism of action in MM (monoclonal antibodies, deacetylase inhibitors, and so on) will be discussed in this review.